(Q45068171)

9 December 2017

title

Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses (English)

1 reference

9 December 2017

1 reference

4

Per Johan Klasse

1 reference

9 December 2017

8

John P Moore

1 reference

9 December 2017

Steven M Wolinsky

1

1 reference

9 December 2017

Ronald S Veazey

2

1 reference

9 December 2017

Kevin J Kunstman

3

1 reference

9 December 2017

Jason Dufour

5

1 reference

9 December 2017

Andre J Marozsan

6

1 reference

9 December 2017

Martin S Springer

7

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

9 December 2017

1 reference

9 December 2017

volume

328

1 reference

9 December 2017

issue

1

1 reference

9 December 2017

page(s)

19-29

1 reference

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Cell surface receptors, virus entry and tropism of primate lentiviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Increased replication of T-cell-tropic HIV strains and CXC-chemokine receptor-4 induction in T cells treated with macrophage inflammatory protein (MIP)-1alpha, MIP-1beta and RANTES beta-chemokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Chemokine receptors and HIV entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

T cell dynamics in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Human immunodeficiency virus type 1 coreceptor preferences determine target T-cell depletion and cellular tropism in human lymphoid tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Rapid and irreversible CD4+ T-cell depletion induced by the highly pathogenic simian/human immunodeficiency virus SHIV(DH12R) is systemic and synchronous

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Early Control of Highly Pathogenic Simian Immunodeficiency Virus/Human Immunodeficiency Virus Chimeric Virus Infections in Rhesus Monkeys Usually Results in Long-Lasting Asymptomatic Clinical Outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

CXCR4-tropic HIV-1 suppresses replication of CCR5-tropic HIV-1 in human lymphoid tissue by selective induction of CC-chemokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Novel therapies based on mechanisms of HIV-1 cell entry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophagetropic isolates of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Surface CD4 Is Critical to in Vitro HIV Infection of Human Alveolar Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Coreceptor choice and T cell depletion by R5, X4, and R5X4 HIV-1 variants in CCR5-deficient (CCR5delta32) and normal human lymphoid tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

The dynamics of CD4+ T-cell depletion in HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

HIV-1 entry inhibitors: evading the issue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

The entry of entry inhibitors: a fusion of science and medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

New therapeutics that modulate chemokine networks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.021

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2004.07.021

1 reference

9 December 2017

1 reference